20 至 24 孕周行扩张刮宫术的 Rh 阴性患者的胎儿-母体出血评估：一项回顾性队列研究。
Fetomaternal hemorrhage assessment in Rh-negative patients undergoing dilation and evacuation between 20 and 24 weeks' gestational age: A retrospective cohort study.
机构信息
Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia PA, United States.
Department of Obstetrics and Gynecology, Pennsylvania Hospital, Philadelphia, PA, United States.
出版信息
Contraception. 2022 Jun;110:27-29. doi: 10.1016/j.contraception.2022.02.001. Epub 2022 Feb 19.
OBJECTIVE
To estimate the rate of requiring more than one 300-mcg Rh D immune globulin dose for fetomaternal hemorrhage (FMH) at the time of second-trimester dilation and evacuation (D + E).
STUDY DESIGN
We performed a retrospective cohort analysis of patients at greater than 20 weeks' gestation who underwent D + E, had Rh D-negative blood type, and received FMH quantification testing.
RESULTS
Of 25 eligible patients, 24 had negative quantification of FMH; one had positive quantification that did not meet the clinical threshold for additional dosing.
CONCLUSIONS
The absolute risk of requiring additional Rh D immune globulin after D+E for pregnancies greater than 20 weeks' gestation was 0%.
目的
评估在妊娠中期扩张和排空术（D+E）时，因胎儿母亲出血（FMH）需要不止一剂 300 微克 Rh D 免疫球蛋白的几率。
研究设计
我们对大于 20 周妊娠、行 D+E、Rh D 阴性血且接受 FMH 定量检测的患者进行了回顾性队列分析。
结果
25 名符合条件的患者中，24 名 FMH 定量检测为阴性；1 名 FMH 定量检测为阳性，但未达到追加剂量的临床阈值。
结论
对于大于 20 周妊娠的 D+E 后需要额外 Rh D 免疫球蛋白的绝对风险为 0%。
Zotero 插件